AI Engines For more Details: Perplexity Kagi Labs You
Anti-inflammatory Effects: Auranofin belongs to a class of medications known as disease-modifying antirheumatic drugs (DMARDs). It works by exerting anti-inflammatory effects, helping to reduce joint inflammation, swelling, and pain associated with rheumatoid arthritis.
Disease Modification: Auranofin is considered a disease-modifying agent because it can slow down the progression of rheumatoid arthritis, prevent joint damage, and preserve joint function when used consistently over time.
Gold Therapy: Auranofin is a gold-containing compound and is classified as a disease-modifying antirheumatic drug (DMARD). Historically, gold-based compounds were commonly used in the treatment of rheumatoid arthritis, but their use has decreased with the advent of newer DMARDs such as methotrexate and biologic agents.
Oral Administration: Auranofin is typically administered orally in the form of tablets. The dosage and frequency of administration may vary depending on the severity of the rheumatoid arthritis and individual patient response.
Side Effects: Like all medications, auranofin can cause side effects. Common side effects may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, or abdominal pain. Some individuals may experience skin rash, itching, or mucocutaneous reactions. A rare but serious side effect is bone marrow suppression, which can lead to decreased production of blood cells (anemia, leukopenia, thrombocytopenia).
Monitoring: Patients taking auranofin require regular monitoring by their healthcare provider to assess treatment response and monitor for potential side effects. Blood tests may be performed to monitor liver function, kidney function, and blood cell counts.
Contraindications: Auranofin is contraindicated in individuals with known hypersensitivity to gold or any other component of the medication. It should be used with caution in patients with a history of significant gastrointestinal disorders or hematologic abnormalities.
Pregnancy and Lactation: Auranofin is not recommended for use during pregnancy or lactation unless the potential benefits outweigh the risks. Women of childbearing age should use effective contraception while taking auranofin.
Drug Interactions: Auranofin may interact with other medications, including certain antibiotics, anticoagulants, and immunosuppressants. Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid potential drug interactions.
Long-Term Use: Auranofin is generally used for the long-term management of rheumatoid arthritis. It may take several weeks to months to achieve maximum therapeutic benefit. Patients should continue taking the medication as directed by their healthcare provider, even if they start to feel better.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.5 | 0.3 | 0.67 |
| ADHD | 5.1 | 0.6 | 7.5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 2.9 | -0.04 |
| Allergies | 6.3 | 4.3 | 0.47 |
| Allergy to milk products | 2 | 1 | 1 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 7.4 | 7.7 | -0.04 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.7 | 0.9 | 3.11 |
| Ankylosing spondylitis | 4.1 | 1.8 | 1.28 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 1.5 | 0.3 | 4 |
| Asthma | 5.9 | 3.4 | 0.74 |
| Atherosclerosis | 2.1 | 2.4 | -0.14 |
| Atrial fibrillation | 4.1 | 2.5 | 0.64 |
| Autism | 11.3 | 10.7 | 0.06 |
| Autoimmune Disease | 1.1 | 1 | 0.1 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 3.9 | 3.9 | |
| Bipolar Disorder | 1.8 | 1.7 | 0.06 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.9 | 3.4 | -2.78 |
| Carcinoma | 4.4 | 2.6 | 0.69 |
| Celiac Disease | 3 | 4.3 | -0.43 |
| Cerebral Palsy | 1.8 | 1.3 | 0.38 |
| Chronic Fatigue Syndrome | 6 | 7.7 | -0.28 |
| Chronic Kidney Disease | 4.6 | 3.4 | 0.35 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.4 | 2 | 0.2 |
| Chronic Urticaria (Hives) | 0.8 | 1.8 | -1.25 |
| Coagulation / Micro clot triggering bacteria | 1.2 | 1.3 | -0.08 |
| Cognitive Function | 3.1 | 1.6 | 0.94 |
| Colorectal Cancer | 7.7 | 2.2 | 2.5 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.8 | 3 | -0.67 |
| COVID-19 | 10.9 | 15.4 | -0.41 |
| Crohn's Disease | 9.2 | 6.9 | 0.33 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.9 | -1.9 | |
| deep vein thrombosis | 2.5 | 1.4 | 0.79 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 12.8 | 11 | 0.16 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 2.6 | -0.53 |
| Endometriosis | 2.3 | 2 | 0.15 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.3 | 2.8 | 0.18 |
| erectile dysfunction | 0.8 | 0.3 | 1.67 |
| Fibromyalgia | 3.7 | 2.6 | 0.42 |
| Functional constipation / chronic idiopathic constipation | 5.7 | 4.9 | 0.16 |
| gallstone disease (gsd) | 3.6 | 1.6 | 1.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 2.7 | 2.4 | 0.13 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.6 | 1 | 1.6 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2.6 | -1.89 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 4.4 | 2.2 | 1 |
| Heart Failure | 4.2 | 2.4 | 0.75 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.3 | 0.6 | 1.17 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.6 | -0.2 |
| hyperglycemia | 1.8 | 2.2 | -0.22 |
| Hyperlipidemia (High Blood Fats) | 1.3 | 0.3 | 3.33 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.2 | 6.8 | -0.31 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 2.9 | 0.3 | 8.67 |
| IgA nephropathy (IgAN) | 1.9 | 5.5 | -1.89 |
| Inflammatory Bowel Disease | 9.7 | 11.5 | -0.19 |
| Insomnia | 2.5 | 3.5 | -0.4 |
| Intelligence | 1.4 | 0.6 | 1.33 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 8.8 | 6.4 | 0.38 |
| ischemic stroke | 2.6 | 1.1 | 1.36 |
| Liver Cirrhosis | 8 | 5.3 | 0.51 |
| Long COVID | 8.1 | 9.3 | -0.15 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.9 | 1.6 | -0.78 |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 1 | 1.1 |
| Metabolic Syndrome | 8.3 | 9.5 | -0.14 |
| Mood Disorders | 13.4 | 8.9 | 0.51 |
| multiple chemical sensitivity [MCS] | 1.7 | 0.1 | 16 |
| Multiple Sclerosis | 8.4 | 7 | 0.2 |
| Multiple system atrophy (MSA) | 2.3 | 0.7 | 2.29 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 0.3 | 3.6 | -11 |
| Neuropathy (all types) | 1.2 | 1.6 | -0.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.8 | 5.9 | -0.02 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 11.6 | 10.6 | 0.09 |
| obsessive-compulsive disorder | 5.8 | 4.8 | 0.21 |
| Osteoarthritis | 2.7 | 1.6 | 0.69 |
| Osteoporosis | 1.9 | 1.9 | 0 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 9.4 | 7.7 | 0.22 |
| Polycystic ovary syndrome | 7.3 | 3.7 | 0.97 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 3.2 | -0.07 |
| Psoriasis | 3.8 | 4 | -0.05 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9.5 | 4.7 | 1.02 |
| Rosacea | 1.2 | 1.2 | 0 |
| Schizophrenia | 7.8 | 3.5 | 1.23 |
| scoliosis | 0.3 | 1.2 | -3 |
| Sjögren syndrome | 2.6 | 3.2 | -0.23 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 0.6 | 1.67 |
| Stress / posttraumatic stress disorder | 3.1 | 3.3 | -0.06 |
| Systemic Lupus Erythematosus | 4.8 | 2.4 | 1 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1.3 | 0.3 | 3.33 |
| Type 1 Diabetes | 5 | 4.4 | 0.14 |
| Type 2 Diabetes | 9.2 | 8.4 | 0.1 |
| Ulcerative colitis | 6.3 | 8.8 | -0.4 |
| Unhealthy Ageing | 6.8 | 2.9 | 1.34 |
| Vitiligo | 2.5 | 2 | 0.25 |
